NOVAFED Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Novafed, and what generic alternatives are available?
Novafed is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in NOVAFED is pseudoephedrine hydrochloride. There is one drug master file entry for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the pseudoephedrine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Novafed
A generic version of NOVAFED was approved as pseudoephedrine hydrochloride by L PERRIGO CO on February 26th, 1999.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for NOVAFED?
- What are the global sales for NOVAFED?
- What is Average Wholesale Price for NOVAFED?
Summary for NOVAFED
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 1,703 |
| DailyMed Link: | NOVAFED at DailyMed |
US Patents and Regulatory Information for NOVAFED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | NOVAFED | pseudoephedrine hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 017603-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
